São apresentados os resultados de um ensaio clínico usando barbexaclone (ciclo-hexil-aminopropano) associado com fenil-etil-barbitúrico, como único anti-convulsivante. Foram selecionados 70 pacientes dos quais 36 eram do sexo feminino e 34 do sexo masculino, sendo 52 crianças e 18 adultos. Todos apresentavam crises de epilepsia tipo grande-mal e tiveram duas ou mais crises antes de serem incluídos na pesquisa. Cinqüenta e três pacientes foram observados durante 18 meses, dos quais 96% ficaram livres de crises neste período. Os níveis plasmáticos dos barbitúricos foram determinados em 20 pacientes. Nestes pacientes o controle completo das crises atingiu 89%. A mensuração dos níveis plasmáticos dos anticonvulsivantes tem demonstrado ser um guia terapêutico útil e seguro no tratamento de epilepsia.

The results of the use of barbexaclone (ciclo-hexil-aminopropan) in association with fenil-etil-barbiturate, as a single anticonvulsant drug in a clinical and therapeutic trial are reported. Seventy patients, 36 women and 34 men, 52 children and 18 adults, all of them with two or more epileptic grand-mal seizures at the begining of treatment, were selected. In 53 patients a complete 18 months follow-up observation was performed. In this group of patients, 96% of them were free of seizures during the observation time. In 20 patients the barbiturate plasma concentration was measured. For these patients, the effectiveness of the treatment was up to 89%, in terms of complete control of convulsive crises. The measurements of the plasma level of anticonvulsants has shown to be most useful and a safe therapeutic guide in the treatment of epilepsies.